Study Demonstrates Epigenetic Predictors of Genome Function
News Feb 07, 2007
Researchers from the Ludwig Institute for Cancer Research (LICR) and the University of California, San Diego (UCSD), along with NimbleGen Systems, Inc., are the first to predict and map epigenetic events to the regulation of gene transcription and function of DNA sequence, according to a paper published online February 4 in Nature Genetics.
While the DNA sequence can identify genes within the genome, it cannot answer the more fundamental questions of how, when and where those genes are expressed. However, the LICR team and collaborators have developed a method to identify and predict the promoter and enhancer regions that switch on transcription, which is the first step in gene expression.
This study is an important step towards large-scale functional annotation of enhancers, which establish the rate at which gene expression occurs and determine the tissues in which genes are expressed.
“The human genome is packaged within each cell by chromatin, a structure composed of DNA wrapped around proteins called histones,” explains lead author Nathaniel Heintzman, a researcher from LICR and the UCSD Biomedical Sciences Graduate Program.
“We used genome-scale approaches to analyze the chromatin architecture in human cells and discovered distinct signatures of modified histones that correspond to known promoters and enhancers. These findings enabled us to generate computational algorithms that identified hundreds of novel genomic regions with regulatory potential.”
Moreover, says Heintzman, this histone code was able to accurately distinguish between promoters, from which gene transcription is directly initiated, and enhancer regions - some of which are very distant from the target gene - to which transcription-activating cofactors bind.
According to LICR’s Dr. Bing Ren, the study’s senior author and assistant professor at UCSD’s Department of Cellular and Molecular Medicine, the method is widely applicable, and its unbiased approach is likely to yield new information on gene expression and how it is altered in disease.
“The beauty of this approach is that it utilizes a chemical signature present on histones but not DNA. Existing methods to predict enhancers rely on the DNA sequence alone, but these are inadequate because we have an incomplete understanding of the sequence features that identify enhancers. The elucidation of a common histone modification signature will enable scientists to quickly identify enhancers and promoters for a gene, which will lead in turn to rapid identification of factors that control its expression.”
This method might also be used to identify the disruptions in gene networks that occur during cancer progression, says Dr. Ren, which might lead to novel strategies for cancer diagnosis.
The LICR and UCSC researchers used NimbleGen’s whole-genome human ChIP arrays to perform the study.
GlaxoSmithKline plc (GSK) has launched a five-year, $67 million collaboration with the San Francisco and Berkeley campuses of the University of California to build a state-of-the-art laboratory. The goal is to use CRISPR technologies to explore how genes cause disease and to rapidly accelerate the discovery of new drugs.